Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Compugen Ltd.    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
03/18/2019 03/19/2019 03/20/2019 03/24/2019 03/25/2019 Date
1318(c) 1348(c) 1353(c) 1286(c) 1284 Last
13 156 25 388 10 669 21 107 1 093 Volume
-0.15% +2.28% +0.37% -4.95% -0.16% Change
More quotes
Financials (ILS)
Sales 2019 32,8 M
EBIT 2019 -112 M
Net income 2019 -142 M
Debt 2019 17,3 M
Yield 2019 -
Sales 2020 33,0 M
EBIT 2020 -114 M
Net income 2020 -167 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 24,5x
Capi. / Sales2020 23,9x
Capitalization 786 M
More Financials
Company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of... 
More about the company
Surperformance© ratings of Compugen Ltd.
Trading Rating : - Investor Rating :
More Ratings
Latest news on COMPUGEN LTD.
03/12COMPUGEN : Announces Issuance of Two U.S. Composition of Matter Patents for COM7..
PU
03/05COMPUGEN : to Present at the Cowen and Company 39th Annual Health Care Conferenc..
PR
01/22COMPUGEN : Announces Publication of Two Peer-Reviewed Papers Demonstrating the R..
PU
01/15COMPUGEN : s Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO..
AQ
2018New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Bio..
AQ
2018COMPUGEN : 3Q Earnings Snapshot
AQ
2018COMPUGEN LTD. : quaterly earnings release
2018COMPUGEN THIRD QUARTER 2018 CONFEREN : 30 am et
PR
2018COMPUGEN : BMS and Compugen join forces on solid tumour clinical trials
AQ
2018BRISTOL MYERS SQUIBB : BMS invests $12m in cancer immunotherapy tie-up with Comp..
AQ
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGEN LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Anat Cohen-Dayag President, Chief Executive Officer & Director
Paul Jai Sekhri Chairman
Ari Krashin Chief Operating & Financial Officer
Zurit Levine Vice President-Research & Discovery
Henry Adewoye Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
COMPUGEN LTD.51.96%217
IQVIA HOLDINGS INC21.93%28 018
CELLTRION, INC.--.--%22 489
LONZA GROUP13.27%21 615
INCYTE CORPORATION34.20%18 267
SEATTLE GENETICS, INC.30.59%11 880